Moderna, Inc.
- mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222
- Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083
CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine.
"We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stéphane Bancel, Chief Executive Officer of Moderna. "mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market."
In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222. Importantly, this benefit was most acutely seen in participants over the age of 65 years, the population that remains at highest risk for severe outcomes from COVID-19. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events included headache, fatigue, myalgia and chills.
The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.
The storage, shelf life and pre-filled syringe presentation of mRNA-1283 could alleviate healthcare provider burden and potentially increase access into new settings to serve public health. A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Spikevax® is a registered trademark of Moderna.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential longer refrigerator shelf life and storage advantages of mRNA-1283 compared to Spikevax; and the ability of mRNA-1283 to maintain effectiveness compared to Spikevax. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Elise Meyer
Sr. Director, Corporate Communications
+1 617-852-7041
Elise.Meyer@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New APAC Partnership with Matter Brings Market Logic Software's Always-On Insights Solutions to Local Brand and Experience Leaders16.12.2025 07:30:00 CET | Press release
BERLIN, DE / ACCESS Newswire / December 16, 2025 / Market Logic Software, the market-leading SaaS provider of insight management solutions, has announced a partnership with Matter, a New Zealand-based intelligence company for brand builders and experience creators. This collaboration marks an exciting step in Market Logic's expansion across APAC, particularly in New Zealand and Australia, where Matter is working closely with local brands that want to deepen their customer and market understanding. Together, Market Logic and Matter will empower APAC businesses to uncover unique insights faster and take swifter action. By combining the power of Market Logic's AI-powered insights platform, DeepSights, with the data, research and measurement expertise of Matter, the two companies will help ambitious local brands drive international growth through intelligence. "New Zealand and Australia are home to exceptional brands who are no strangers to innovation and creativity," said Oliver Allen. "B
AI and Cybersecurity Leader, SecureAuth, Appoints Geoffrey Mattson to Help Enterprises Secure Complex Human, Machine, and AI-agent Identities10.12.2025 17:30:00 CET | Press release
IRVINE, CALIFORNIA / ACCESS Newswire / December 10, 2025 / SecureAuth, a leader in AI-driven identity security, today announced the appointment of Geoffrey Mattson as Chief Executive Officer. Mattson's appointment marks the beginning of the company's next phase of growth as enterprises confront a rapid rise in AI agents with real authority, a shift that is increasing the complexity of business relationships and driving urgent demand for modern identity security. The Board of Directors thanks outgoing CEO Joseph Dhanapal, who will remain as a strategic advisor. During his tenure, SecureAuth invested heavily in creating a next generation security platform, featuring our market leading, AI-driven risk engine. With this platform in place, SecureAuth is positioned to capture accelerating demand for identity and access management as agentic AI transforms identity from a static access check into a dynamic control plane for managing complex human, machine, and AI-driven relationships. Mattson
Nasdaq Verafin Joins Global Anti-Scam Alliance10.12.2025 15:00:00 CET | Press release
THE HAGUE, NL / ACCESS Newswire / December 10, 2025 / The Global Anti-Scam Alliance (GASA) is pleased to announce that Nasdaq Verafin has joined GASA as a Foundation Member, strengthening the global effort to combat scams, financial crime, and digital fraud. As fraud tactics continue to evolve across borders and digital channels, cross-sector collaboration has become essential to protecting consumers and building safer financial ecosystems. Nasdaq Verafin's participation marks a meaningful step forward in the shared mission to advance trust, transparency, and resilience across the globe. In addition to joining the global effort, Nasdaq Verafin will join both the Brazil and Mexico chapters of GASA to partner with stakeholders across the financial ecosystem in Latin America, bolstering regional initiatives to combat financial crime. "Criminals are innovating at an unprecedented rate, taking advantage of information siloes and the shortcomings of legacy technology to avoid detection. We a
TIS Helps Treasury Teams Navigate the Ongoing ISO 20022 Transition After the 2025 Banking Deadline10.12.2025 14:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / December 10, 2025 / Treasury Intelligence Solutions (TIS), a leading cloud-based platform for payments and cash management, is future-proofing organizations with specialized translation services in the wake of the recent November 2025 ISO 20022 deadline. A major turning point for the financial industry, SWIFT now requires banks to move their cross-border payment messages to ISO 20022. As a result, treasury teams are already seeing differences in how their banks send and receive payment information. Adapting to these changes will require a strategic approach to modernizing systems and processes. ISO 20022 replaces a patchwork of older standards with a single approach to structuring payment data. The new universal standard is designed to reduce confusion across markets, improve data quality, and support the level of transparency that regulators around the globe now expect. Moving to ISO 20022 payments takes time and strategic vision, especially when legacy
Majority of Australian Parents (65%) and U.S. Parents 58% Support Social Media Ban for Under 16s, but Kids Say It Risks Cutting Them Off from Key Connections9.12.2025 15:00:00 CET | Press release
New survey of 4,000 parents and children in the U.S. and Australia reveals sharp generational divides in support, fears, mental health expectations, and belief in government enforcement. WASHINGTON, DC / ACCESS Newswire / December 9, 2025 / The Family Online Safety Institute (FOSI) released new research today examining how parents and children in the United States and Australia view social media bans for anyone under 16. The findings reveal strong parental support for such bans, in contrast with widespread concern from children who fear losing friendships and support systems that exist primarily online. The research arrives as Australia implements a national under 16 social media ban, placing global attention on how the policy will affect youth and their families. FOSI's study surveyed 4,000 parents and children ages 10 to 17 to understand how both groups feel about restrictions, enforcement, and the broader impact of social media on daily life. Support for the Ban: Parents vs Children
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom